Tri Locum Partners LP Has $30.75 Million Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Tri Locum Partners LP lessened its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 28.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,021,008 shares of the company’s stock after selling 414,857 shares during the quarter. Teva Pharmaceutical Industries accounts for about 4.3% of Tri Locum Partners LP’s investment portfolio, making the stock its 11th largest position. Tri Locum Partners LP’s holdings in Teva Pharmaceutical Industries were worth $30,753,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also bought and sold shares of the stock. Legal & General Group Plc boosted its stake in shares of Teva Pharmaceutical Industries by 6.8% in the 4th quarter. Legal & General Group Plc now owns 3,608,387 shares of the company’s stock valued at $112,618,000 after purchasing an additional 228,189 shares in the last quarter. Norges Bank acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $1,098,060,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Teva Pharmaceutical Industries by 8.0% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,082,578 shares of the company’s stock worth $33,506,000 after purchasing an additional 80,106 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in Teva Pharmaceutical Industries during the 1st quarter valued at about $9,126,000. Finally, TD Asset Management Inc lifted its holdings in Teva Pharmaceutical Industries by 47.1% during the 4th quarter. TD Asset Management Inc now owns 369,023 shares of the company’s stock valued at $11,517,000 after purchasing an additional 118,075 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 9.1%

Shares of NYSE TEVA opened at $34.55 on Thursday. Teva Pharmaceutical Industries Ltd. has a 1-year low of $14.99 and a 1-year high of $37.35. The company has a 50-day moving average of $33.19 and a two-hundred day moving average of $32.69. The company has a market cap of $39.73 billion, a PE ratio of 25.98, a P/E/G ratio of 3.35 and a beta of 0.86. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The business had revenue of $4.14 billion during the quarter. As a group, equities analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In other news, insider Mark Sabag sold 144,180 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, May 1st. The stock was sold at an average price of $34.99, for a total value of $5,044,858.20. Following the completion of the sale, the insider directly owned 80,760 shares of the company’s stock, valued at approximately $2,825,792.40. This trade represents a 64.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Richard Daniell sold 30,000 shares of the business’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total value of $1,062,000.00. Following the sale, the executive vice president owned 55,755 shares of the company’s stock, valued at approximately $1,973,727. The trade was a 34.98% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 444,673 shares of company stock valued at $15,582,369 over the last quarter. Corporate insiders own 0.54% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Truist Financial raised their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. JPMorgan Chase & Co. increased their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. Piper Sandler raised their price target on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a report on Tuesday. Wall Street Zen downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Finally, UBS Group boosted their price objective on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

Teva Pharmaceutical Industries News Roundup

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Innovative medicines delivered strong growth. Teva said its key innovative brands grew 43% year over year in local-currency terms to more than $1 billion in second-quarter revenue. The company raised its 2026 outlook for all three key brands, supporting its strategy of shifting beyond lower-margin generics. Teva Delivers Strong Q2 Results and Raises Outlook
• Positive Sentiment: UZEDY momentum was particularly encouraging. U.S. sales of the long-acting schizophrenia treatment reached a record $77 million, up 43% year over year. Teva raised its 2026 UZEDY revenue forecast to $270 million-$290 million from $250 million-$280 million previously. UZEDY Record Q2 Net Sales and Outlook
• Positive Sentiment: Revenue guidance exceeded expectations. Teva forecast 2026 revenue of $16.5 billion-$16.9 billion, broadly aligned with the $16.7 billion consensus but described by investors as better than expected. Piper Sandler also raised its price target to $44 from $42 and maintained an Overweight rating. Teva Stock Rises After Earnings
• Neutral Sentiment: Options activity reflected increased bullish interest. Traders purchased 23,688 call options, approximately 136% above typical daily call volume. This may amplify short-term momentum, but it is not a fundamental indicator of business performance.
• Negative Sentiment: Quarterly profitability fell short. Teva reported second-quarter EPS of $0.02, below the $0.08 consensus and down from $0.66 a year earlier. Revenue of $4.14 billion exceeded estimates of $4.02 billion but declined roughly 1% year over year, primarily because of weaker generics revenue. Teva Quarterly Earnings Report
• Negative Sentiment: EPS guidance was below Wall Street expectations. Teva projected 2026 EPS of $1.91-$2.11 versus the $2.17 consensus, creating a counterweight to the improved revenue outlook and strong branded-drug performance.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.